CONTRIBUTION OF CHROMOSOMES ANALYSIS AND MOLECULAR STUDIES IN THE MANAGEMENT OF CHRONIC MYELOID LEUKEMIA IN KWAZULU-NATAL AT INKOSI ALBERT LUTHULI HOSPTITAL OVER 2 YEARS 2008-2009

Fabien Ntaganda, Vincent Louis Naicker

Abstract


In South Africa chronic myeloid leukemia (CML) is a reality with an incidence of 460 new cases per annum. Imatinib was first approved in 2007 in KwaZulu-Natal, for patients diagnosed with CML. These patients need a strict cytogenetic and molecular monitoring for response to treatment. In KwaZulu- Natal cytogenetic and molecular have been introduced in the department of haematology since 2003, and are used to monitor the disease in addition to diagnosis. In our study we will examine the role of cytogenetic and molecular studies in CML patients over 2 years and its impact in the clinical management of patients.